Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDI7SA)

• Drug Name: MEDI3506 Drug Info
• Synonyms: Tozorakimab

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMDI7SA

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-33 (IL33)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tozorakimab	DMCXN80	Acute respiratory failure	CB41.0	Phase 3	[2]
SAR440340	DMKYXSS	Chronic obstructive pulmonary disease	CA22	Phase 3	[3]
Itepekimab	DMR8NDD	Chronic obstructive pulmonary disease	CA22	Phase 3	[3]
AMG 282	DM92YWD	Asthma	CA23	Phase 1	[4]
PF-07264660	DM0GI2H	Atopic dermatitis	EA80	Phase 1	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-33 (IL33)	TT5MD4P	IL33_HUMAN	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
• [2] ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691.
• [3] Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668.
• [4] Clinical pipeline report, company report or official report of Amgen.
• [5] Clinical pipeline report, company report or official report of Pfizer